AVBP
ArriVent BioPharma, Inc. Common Stock
Biotechnology
Market Cap$1.25B
5Y Perf.+36.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
AVBP vs NUVL vs KYMR vs ERAS
Revenue, margins, valuation, and 5-year total return — side by side.
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.74B
5Y Perf.+40.1%
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$7.03B
5Y Perf.+162.6%
ERAS
Erasca, Inc.
Biotechnology
Market Cap$2.87B
5Y Perf.+506.0%
AVBP vs NUVL vs KYMR vs ERAS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AVBP | NUVL | KYMR | ERAS |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $1.25B | $7.74B | $7.03B | $2.87B |
| Revenue (TTM) | $0.00 | $0.00 | $51M | $0.00 |
| Net Income (TTM) | $-166M | $-450M | $-315M | $-128M |
| Gross Margin | — | — | 33.2% | — |
| Operating Margin | — | — | -7.0% | — |
| Total Debt | $14K | $0.00 | $82M | $52M |
| Cash & Equiv. | $46M | $262M | $357M | $68M |
AVBP vs NUVL vs KYMR vs ERAS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AVBP
NUVL
KYMR
ERAS
| Stock | Jan 24 | May 26 | Return |
|---|---|---|---|
| ArriVent BioPharma,… (AVBP) | 100 | 136.9 | +36.9% |
| Nuvalent, Inc. (NUVL) | 100 | 140.1 | +40.1% |
| Kymera Therapeutics… (KYMR) | 100 | 262.6 | +162.6% |
| Erasca, Inc. (ERAS) | 100 | 606.0 | +506.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AVBP vs NUVL vs KYMR vs ERAS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ERAS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Kymera Therapeutics, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
AVBP
ArriVent BioPharma, Inc. Common Stock
The Specific-Use Pick
AVBP plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
NUVL
Nuvalent, Inc.
The Long-Run Compounder
NUVL is the clearest fit if your priority is long-term compounding and defensive.
- 461.5% 10Y total return vs KYMR's 158.8%
- Beta 1.01, current ratio 15.27x
Best for: long-term compounding and defensive
KYMR
Kymera Therapeutics, Inc.
The Niche Pick
KYMR is the #2 pick in this set and the best alternative if efficiency is your priority.
- -22.3% ROA vs AVBP's -58.1%
Best for: efficiency
ERAS
Erasca, Inc.
The Income Pick
ERAS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.62
- EPS growth 16.9%
- Lower volatility, beta 0.62, Low D/E 12.3%, current ratio 9.84x
- 19.8% revenue growth vs AVBP's -42.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ERAS | 19.8% revenue growth vs AVBP's -42.5% |
| Quality / Margins | ERAS | 4.0% margin vs KYMR's -6.1% |
| Stability / Safety | ERAS | Beta 0.62 vs AVBP's 1.16 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ERAS | +6.3% vs NUVL's +47.0% |
| Efficiency (ROA) | KYMR | -22.3% ROA vs AVBP's -58.1% |
AVBP vs NUVL vs KYMR vs ERAS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKYMRLAGGINGNUVL
Who Leads Where
KYMR leads in 2 of 6 categories
ERAS leads 1 • AVBP leads 0 • NUVL leads 0 • 2 tied
Explore the data ↓NUVLNuvalent, Inc.
0leads
AVBPArriVent BioPharma, I…
0leads
ERASErasca, Inc.
1leads
KYMRKymera Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs ERASvs AVBPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYMR1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KYMR6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ERAS4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYMR leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KYMR and ERAS operate at a comparable scale, with $51M and $0 in trailing revenue.
| Metric | AVBPArriVent BioPharm… | NUVLNuvalent, Inc. | KYMRKymera Therapeuti… | ERASErasca, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $51M | $0 |
| EBITDAEarnings before interest/tax | -$133M | -$346M | -$352M | -$141M |
| Net IncomeAfter-tax profit | -$166M | -$450M | -$315M | -$128M |
| Free Cash FlowCash after capex | -$161M | -$313M | -$244M | -$98M |
| Gross MarginGross profit ÷ Revenue | — | — | +33.2% | — |
| Operating MarginEBIT ÷ Revenue | — | — | -7.0% | — |
| Net MarginNet income ÷ Revenue | — | — | -6.1% | — |
| FCF MarginFCF ÷ Revenue | — | — | -4.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +55.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -13.1% | -17.8% | +13.4% | 0.0% |
KYMR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — AVBP and KYMR each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | AVBPArriVent BioPharm… | NUVLNuvalent, Inc. | KYMRKymera Therapeuti… | ERASErasca, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $1.3B | $7.7B | $7.0B | $2.9B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $7.5B | $6.8B | $2.9B |
| Trailing P/EPrice ÷ TTM EPS | -6.83x | -18.00x | -23.33x | -14.67x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 179.28x | — |
| Price / BookPrice ÷ Book value/share | 3.69x | 6.13x | 4.60x | 5.59x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — AVBP and KYMR each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
KYMR leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
KYMR delivers a -25.0% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-62 for AVBP. AVBP carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ERAS's 0.12x. On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs NUVL's 1/9, reflecting mixed financial health.
| Metric | AVBPArriVent BioPharm… | NUVLNuvalent, Inc. | KYMRKymera Therapeuti… | ERASErasca, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -62.5% | -42.8% | -25.0% | -36.7% |
| ROA (TTM)Return on assets | -58.1% | -37.8% | -22.3% | -30.4% |
| ROICReturn on invested capital | — | -32.5% | -24.9% | -39.2% |
| ROCEReturn on capital employed | — | -34.4% | -27.2% | -42.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.00x | — | 0.05x | 0.12x |
| Net DebtTotal debt minus cash | -$46M | -$262M | -$275M | -$16M |
| Cash & Equiv.Liquid assets | $46M | $262M | $357M | $68M |
| Total DebtShort + long-term debt | $14,000 | $0 | $82M | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | -26.85x | -2119.53x | — |
KYMR leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ERAS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $56,149 today (with dividends reinvested), compared to $5,806 for ERAS. Over the past 12 months, ERAS leads with a +628.1% total return vs NUVL's +47.0%. The 3-year compound annual growth rate (CAGR) favors ERAS at 52.4% vs AVBP's 13.8% — a key indicator of consistent wealth creation.
| Metric | AVBPArriVent BioPharm… | NUVLNuvalent, Inc. | KYMRKymera Therapeuti… | ERASErasca, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +41.8% | +4.4% | +18.3% | +181.9% |
| 1-Year ReturnPast 12 months | +49.4% | +47.0% | +179.8% | +628.1% |
| 3-Year ReturnCumulative with dividends | +47.5% | +178.8% | +210.3% | +253.8% |
| 5-Year ReturnCumulative with dividends | +47.5% | +461.5% | +95.8% | -41.9% |
| 10-Year ReturnCumulative with dividends | +47.5% | +461.5% | +158.8% | -41.9% |
| CAGR (3Y)Annualised 3-year return | +13.8% | +40.7% | +45.9% | +52.4% |
ERAS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NUVL and ERAS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ERAS is the less volatile stock with a 0.62 beta — it tends to amplify market swings less than AVBP's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUVL currently trades 93.2% from its 52-week high vs ERAS's 41.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AVBPArriVent BioPharm… | NUVLNuvalent, Inc. | KYMRKymera Therapeuti… | ERASErasca, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 1.01x | 1.03x | 0.62x |
| 52-Week HighHighest price in past year | $32.14 | $113.02 | $103.00 | $24.28 |
| 52-Week LowLowest price in past year | $16.10 | $63.56 | $28.06 | $1.06 |
| % of 52W HighCurrent price vs 52-week peak | +91.8% | +93.2% | +83.6% | +41.7% |
| RSI (14)Momentum oscillator 0–100 | 52.3 | 48.9 | 50.5 | 35.8 |
| Avg Volume (50D)Average daily shares traded | 508K | 546K | 583K | 7.1M |
Evenly matched — NUVL and ERAS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AVBP as "Buy", NUVL as "Buy", KYMR as "Buy", ERAS as "Buy". Consensus price targets imply 49.2% upside for AVBP (target: $44) vs 34.4% for ERAS (target: $14).
| Metric | AVBPArriVent BioPharm… | NUVLNuvalent, Inc. | KYMRKymera Therapeuti… | ERASErasca, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $44.00 | $144.40 | $118.06 | $13.60 |
| # AnalystsCovering analysts | 6 | 14 | 26 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KYMR leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ERAS leads in 1 (Total Returns). 2 tied.
Best OverallKymera Therapeutics, Inc. (KYMR)Leads 2 of 6 categories
Loading custom metrics...
AVBP vs NUVL vs KYMR vs ERAS: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is AVBP or NUVL or KYMR or ERAS a better buy right now?
Analysts rate ArriVent BioPharma, Inc.
Common Stock (AVBP) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AVBP or NUVL or KYMR or ERAS?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +461. 5%, compared to -41. 9% for Erasca, Inc. (ERAS). Over 10 years, the gap is even starker: NUVL returned +461. 5% versus ERAS's -41. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AVBP or NUVL or KYMR or ERAS?
By beta (market sensitivity over 5 years), Erasca, Inc.
(ERAS) is the lower-risk stock at 0. 62β versus ArriVent BioPharma, Inc. Common Stock's 1. 16β — meaning AVBP is approximately 88% more volatile than ERAS relative to the S&P 500. On balance sheet safety, ArriVent BioPharma, Inc. Common Stock (AVBP) carries a lower debt/equity ratio of 0% versus 12% for Erasca, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — AVBP or NUVL or KYMR or ERAS?
On earnings-per-share growth, the picture is similar: Erasca, Inc.
grew EPS 16. 9% year-over-year, compared to -68. 8% for ArriVent BioPharma, Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AVBP or NUVL or KYMR or ERAS?
ArriVent BioPharma, Inc.
Common Stock (AVBP) is the more profitable company, earning 0. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVBP leads at 0. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AVBP or NUVL or KYMR or ERAS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AVBP or NUVL or KYMR or ERAS better for a retirement portfolio?
For long-horizon retirement investors, Erasca, Inc.
(ERAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62)). Both have compounded well over 10 years (ERAS: -41. 9%, AVBP: +47. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AVBP and NUVL and KYMR and ERAS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.